How were Jacka Resources' earnings last quarter?

Jacka Resources Limited (ASX:JKA) posted its quarterly earnings data on Thursday, March, 1st. The company reported $0.00 EPS for the quarter.

ASX:JKA

Jacka Resources (JKA) Stock Price, News & Analysis

→ Jim Cramer’s “The Biggest Drug Ever” (From Behind the Markets) (Ad)

Free JKA Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Jacka Resources alerts:

Ad Behind the Markets

Jim Cramer’s “The Biggest Drug Ever”

This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.

Unlock the details of this groundbreaking opportunity here...

About Jacka Resources

Jacka Resources Limited engages in the exploration of oil and gas resources. It holds an option to acquire a 5% interest in the Odewayne block located in Somaliland. The company was founded in 2009 and is based in Perth, Australia.

Ad Behind the Markets

Jim Cramer’s “The Biggest Drug Ever”

This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.

Unlock the details of this groundbreaking opportunity here...

JKA Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive JKA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jacka Resources and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/01/2018
Today: 4/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Basic Materials
Industry: Independent Oil & Gas
Sub-Industry: N/A
Current Symbol: ASX:JKA
CUSIP: N/A
CIK: N/A
Web: www.jackaresources.com.au
Phone: +61-8-94810389
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.92
Quick Ratio: 0.82

Sales & Book Value

Annual Sales: $-771,087.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 3.00
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 768,108,992
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Kenneth Charsinsky
E&P Advisor
Mr. Stephen Michael Brockhurst BComm (Age 39)
CA, Company Sec.

Key Competitors

View All Competitors

JKA Stock Analysis - Frequently Asked Questions

How were Jacka Resources' earnings last quarter?: Jacka Resources Limited (ASX:JKA) posted its quarterly earnings data on Thursday, March, 1st. The company reported $0.00 EPS for the quarter.

This page (ASX:JKA) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial